Clinical trial
3-AP in Treating Patients With Advanced or Metastatic Solid Tumors
NCT00390052 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00390052 |
|---|---|
| Title | 3-AP in Treating Patients With Advanced or Metastatic Solid Tumors |
| Official title | A Phase I and Pharmacokinetic Study of Oral 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone(3-AP,Triapine) in the Treatment of Advanced Solid Tumors |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug, Other, Procedure |
| Interventions | triapine, pharmacological study, laboratory biomarker analysis |
| Enrollment | 24 |
| Start date | Dec 1, 2006 |
| Primary completion | Feb 1, 2011 |
| First posted | Oct 19, 2006 |
| Last update posted | Dec 16, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: